Skip to Content
  • Revenues ($M)
    $16,560
  • Revenue Percent Change
    4.3%
  • Profits ($M)
    $1,565
  • Profits Percent Change
    -21.9%
  • Assets ($M)
    $31,748
  • Employees
    25,000
  • Market Value — as of March 31, 2016 ($M)
    $106,848
  • Previous Rank
    195
  • Morning Consult Brand Index
    B+

The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Giovanni Caforio
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, NY
Websitehttp://www.bms.com
Years on Fortune 500 List22
Employees25,000

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$16,5604.3%
Profits ($M)$1,565-21.9%
Assets ($M)$31,748-
Total Stockholder Equity ($M)$14,266-
Market Value — as of March 31, 2016 ($M)$106,848-

Profit Ratios

Profit as % of Revenues9.5%
Profits as % of Assets4.9%
Profits as % of Stockholder Equity11%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.93
EPS % Change (from 2014)-22.5%
EPS % Change (5 year annual rate)-12.3%
EPS % Change (10 year annual rate)-4.8%

Total Return

Total Return to Investors (2015)19.3%
Total Return to Investors (5 year, annualized)25.2%
Total Return to Investors (10 year, annualized)16.4%